ATE316656T1 - Fourier-transformation-massenspektrometrie von komplizierten biologischen proben - Google Patents

Fourier-transformation-massenspektrometrie von komplizierten biologischen proben

Info

Publication number
ATE316656T1
ATE316656T1 AT01958911T AT01958911T ATE316656T1 AT E316656 T1 ATE316656 T1 AT E316656T1 AT 01958911 T AT01958911 T AT 01958911T AT 01958911 T AT01958911 T AT 01958911T AT E316656 T1 ATE316656 T1 AT E316656T1
Authority
AT
Austria
Prior art keywords
complex biological
mass spectrometry
biological samples
fourier transformation
permit
Prior art date
Application number
AT01958911T
Other languages
English (en)
Inventor
Jean-Louis H Dasseux
Roger S Newton
Thomas J Rea
Charles L Bisgaier
Micael E Pape
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Application granted granted Critical
Publication of ATE316656T1 publication Critical patent/ATE316656T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/24—Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Physiology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Analysing Materials By The Use Of Radiation (AREA)
AT01958911T 2000-07-10 2001-07-10 Fourier-transformation-massenspektrometrie von komplizierten biologischen proben ATE316656T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21766300P 2000-07-10 2000-07-10
US09/735,707 US6680203B2 (en) 2000-07-10 2000-12-12 Fourier transform mass spectrometry of complex biological samples

Publications (1)

Publication Number Publication Date
ATE316656T1 true ATE316656T1 (de) 2006-02-15

Family

ID=26912131

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01958911T ATE316656T1 (de) 2000-07-10 2001-07-10 Fourier-transformation-massenspektrometrie von komplizierten biologischen proben

Country Status (10)

Country Link
US (2) US6680203B2 (de)
EP (1) EP1299730B1 (de)
JP (1) JP2004503749A (de)
AT (1) ATE316656T1 (de)
AU (1) AU2001280517A1 (de)
CA (1) CA2415940A1 (de)
DE (1) DE60116882T2 (de)
ES (1) ES2259668T3 (de)
HK (1) HK1051068A1 (de)
WO (1) WO2002004957A2 (de)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969614B1 (en) * 1999-02-16 2005-11-29 The United States Of America As Represented By The Department Of Health And Human Services Methods for the isolation and analysis of cellular protein content
US7057168B2 (en) * 1999-07-21 2006-06-06 Sionex Corporation Systems for differential ion mobility analysis
CA2387500C (en) * 1999-10-20 2007-07-31 Gentra Systems, Inc. Mixing and pouring apparatus with rotatable arm and related vessel
CA2298181C (en) 2000-02-02 2006-09-19 Dayan Burke Goodnough Non-targeted complex sample analysis
AU2001262943A1 (en) 2000-04-14 2001-10-30 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
US7329489B2 (en) * 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
WO2001099043A1 (en) 2000-06-19 2001-12-27 Correlogic Systems, Inc. Heuristic method of classification
US6680203B2 (en) * 2000-07-10 2004-01-20 Esperion Therapeutics, Inc. Fourier transform mass spectrometry of complex biological samples
BR0112667A (pt) * 2000-07-18 2006-05-09 Correlogic Systems Inc processo de distinção entre estados biológicos baseados em padrões ocultos de dados biológicos
US8568766B2 (en) * 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
CA2427014A1 (en) * 2000-11-02 2002-08-22 Cornell Research Foundation, Inc. In vivo multiphoton diagnostic detection and imaging of a neurodegenerative disease
US6585646B2 (en) * 2000-11-29 2003-07-01 Hermetic Diagnostics, Inc. Screening test and procedure using skin patches
EP1344065A2 (de) * 2000-12-14 2003-09-17 Paul Stroobant Proteomische bestimmung durch phagensonden
CA2349265A1 (en) * 2001-05-30 2002-11-30 Andrew Emili Protein expression profile database
US7274015B2 (en) * 2001-08-08 2007-09-25 Sionex Corporation Capacitive discharge plasma ion source
US6727496B2 (en) * 2001-08-14 2004-04-27 Sionex Corporation Pancake spectrometer
CA2464474C (en) * 2001-10-24 2011-12-20 The Regents Of The University Of California Measurement of protein synthesis rates in humans and experimental systems by use of isotopically labeled water
US20040002842A1 (en) * 2001-11-21 2004-01-01 Jeffrey Woessner Methods and systems for analyzing complex biological systems
US20030108876A1 (en) * 2001-12-11 2003-06-12 Speir Johnny Paul Method for the application of FTMS to drug testing
EP1483399B1 (de) * 2002-02-12 2008-10-29 The Regents of the University of California Nichtinvasive messung der biosynthese- und abbaugeschwindigkeiten biologischer moleküle, die einer direkten probenahme unzugänglich oder nicht leicht zugänglich sind, durch einbau einer markierung in metabolische derivate und katabole produkte
US6771369B2 (en) * 2002-03-12 2004-08-03 Analytical Spectral Devices, Inc. System and method for pharmacy validation and inspection
NZ534751A (en) * 2002-03-22 2007-05-31 Phenomenome Discoveries Inc Method of visualizing non-targeted metabolomic data generated from fourier transform ion cyclotron resonance mass spectrometers
AR040711A1 (es) 2002-07-29 2005-04-13 Us Agriculture Un metodo para verificacion de calidad/control de calidad para proceso de bioensayo de alto rendimiento
EP1546364A4 (de) * 2002-07-30 2006-09-06 Univ California Verfahren zur automatischen messung im grossmassstab der molekularen flussgeschwindigkeiten des proteoms oder des organoms mittels massenspektrometrie
US6822223B2 (en) * 2002-08-29 2004-11-23 Siemens Energy & Automation, Inc. Method, system and device for performing quantitative analysis using an FTMS
WO2004021863A2 (en) * 2002-09-04 2004-03-18 The Regents Of The University Of California Methods for measuring rates of replication and death of nfectious microbial agents in an infected host organism
DE60324950D1 (de) * 2002-09-13 2009-01-08 Univ California Verfahren zur messung der geschwindigkeiten des cholesterinrückwärtstransports in vivo als index für anti-artherogenese
US20070248540A1 (en) * 2002-09-16 2007-10-25 The Regents Of The University Of California Biochemical methods for measuring metabolic fitness of tissues or whole organisms
US7544932B2 (en) * 2002-10-21 2009-06-09 The United States Of America, As Represented By The Secretary, Of The Department Of Health And Human Services Contiguous capillary electrospray sources and analytical devices
AU2003291731B2 (en) 2002-11-04 2009-09-10 The Regents Of The University Of California Deuterated glucose or fat tolerance tests for high-throughput measurement of the metabolism of sugars or fatty acids in the body
US20040121305A1 (en) * 2002-12-18 2004-06-24 Wiegand Roger Charles Generation of efficacy, toxicity and disease signatures and methods of use thereof
WO2004081527A2 (en) * 2003-03-10 2004-09-23 Sionex Corporation Systems for differential ion mobility analysis
US7425700B2 (en) 2003-05-22 2008-09-16 Stults John T Systems and methods for discovery and analysis of markers
US7262020B2 (en) * 2003-07-03 2007-08-28 The Regents Of The University Of California Methods for comparing relative flux rates of two or more biological molecules in vivo through a single protocol
EP1649281A4 (de) * 2003-08-01 2007-11-07 Correlogic Systems Inc Mehrere hochauflösende proteomische serummerkmale zum nachweis von eierstockkrebs
US6984820B2 (en) * 2003-11-20 2006-01-10 Siemens Energy & Automation, Inc. Method and apparatus for analyzing hydrocarbon streams
US20050202406A1 (en) 2003-11-25 2005-09-15 The Regents Of The University Of California Method for high-throughput screening of compounds and combinations of compounds for discovery and quantification of actions, particularly unanticipated therapeutic or toxic actions, in biological systems
WO2005060608A2 (en) * 2003-12-11 2005-07-07 Correlogic Systems, Inc. Method of diagnosing biological states through the use of a centralized, adaptive model, and remote sample processing
TW200538738A (en) 2004-02-20 2005-12-01 Univ California Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity
WO2005085838A2 (en) * 2004-03-02 2005-09-15 Vanderbilt University Computational analysis of mass spectroscopic lipid data
US20050201937A1 (en) * 2004-03-11 2005-09-15 The Regents Of The University Of California Temporal or spatial characterization of biosynthetic events in living organisms by isotopic fingerprinting under conditions of imposed isotopic gradients
US20050238577A1 (en) * 2004-03-29 2005-10-27 The Regents Of The University Of California Isolation of epithelial cells or their biochemical contents from excreta after in vivo isotopic labeling
US7651847B2 (en) * 2004-06-22 2010-01-26 The Regents Of The University Of California Methods of oligosaccharide profiling for the detection of cancer
JP2006119017A (ja) * 2004-10-22 2006-05-11 Oki Electric Ind Co Ltd 熱分解ガスクロマトグラフィーを用いた植物の品種判定方法
DK1814590T4 (da) * 2004-11-01 2014-02-24 Amylin Pharmaceuticals Llc Behandling af obesitet og beslægtede sygdomme.
SG123632A1 (en) * 2004-12-15 2006-07-26 Nanyang Polytechnic Method of generating and representing gene differential expression profiles by applying fourier transform
GT200600026A (es) * 2005-01-25 2006-11-07 Bayer Cropscience Sa Metodo para analizar el acido fosforoso, el fosetil-al o ambos simultaneamente
US20070003996A1 (en) * 2005-02-09 2007-01-04 Hitt Ben A Identification of bacteria and spores
JP4118918B2 (ja) * 2005-02-28 2008-07-16 シャープ株式会社 信号品質評価装置、情報記録再生装置、信号品質評価方法、記録条件決定方法、信号品質評価プログラム、信号品質評価プログラムを記録したコンピュータ読み取り可能な記録媒体
EP2368561B1 (de) 2005-04-29 2013-12-04 The Regents of The University of California Peptide und Peptidmimetika zur Behandlung von Pathologien, die durch eine Entzündungsreaktion gekennzeichnet sind
WO2007120154A2 (en) * 2005-05-04 2007-10-25 The Regents Of The University Of California Methods of oligosaccharide profiling for the detection of ocular rosacea
WO2006124628A2 (en) * 2005-05-12 2006-11-23 Correlogic Systems, Inc. A model for classifying a biological sample in relation to breast cancer based on mass spectral data
TW200711660A (en) * 2005-06-10 2007-04-01 Univ California Monitoring two dimensions of diabetes pathogenesis separately or concurrently (insulin sensitivity and beta-cell sufficiency): uses in diagnosis, prognosis, assessment of disease risk, and drug development
EP1875401B1 (de) * 2005-06-30 2014-03-05 BIOCRATES Life Sciences AG Verfahren zur quantitativen analyse von metabolitprofilen
CA2881326A1 (en) * 2005-09-12 2007-03-22 Phenomenome Discoveries Inc. Methods for the diagnosis of colorectal cancer and ovarian cancer health states
WO2007120373A2 (en) * 2006-01-26 2007-10-25 Sionex Corporation Differential mobility spectrometer analyzer and pre-filter apparatus, methods and systems
DK2013619T3 (en) * 2006-04-10 2017-12-04 Wisconsin Alumni Res Found METHODS FOR USING HUMAN EMBYO STEM CELLS FOR EVALUATION OF THE PHARMACEUTICAL SUBSTANCE AND OTHER CHEMICALS
DE102006021493B4 (de) 2006-05-09 2010-04-01 Bruker Daltonik Gmbh Massenspektrometrische Messung mikrobieller Resistenzen
US7742880B2 (en) * 2006-06-20 2010-06-22 Seer Technology, Inc. Apparatus, system, and method for broad spectrum chemical detection
US7806963B2 (en) * 2006-06-20 2010-10-05 Seer Technology, Inc. Apparatus, system, and method for improved power utilization in a gas chromatography sensor
EP2049137A4 (de) 2006-08-08 2013-05-01 Univ California Salicylanilide als verstärker der oralen freisetzung therapeutischer peptide
WO2008033575A2 (en) * 2006-09-15 2008-03-20 Metabolon, Inc. Methods of identifying biochemical pathways
US8395112B1 (en) * 2006-09-20 2013-03-12 Mark E. Bier Mass spectrometer and method for using same
JP4811467B2 (ja) * 2006-11-15 2011-11-09 株式会社島津製作所 質量分析データ解析方法及び装置
US10928366B2 (en) * 2007-01-26 2021-02-23 Sigma-Aldrich Co. Llc Compositions and methods for combining protein precipitation and solid phase extraction
US10434492B2 (en) * 2007-01-26 2019-10-08 Sigma-Aldrich Co. Llc Compositions and methods for solid phase extraction of lipids
TW200849843A (en) * 2007-06-01 2008-12-16 Vivatom Element Co Ltd Communication module having a biomodulator
WO2008156485A1 (en) * 2007-06-19 2008-12-24 Gary Bodily Apparatus, system, and method for broad spectrum chemical detection
BRPI0813002A2 (pt) 2007-06-29 2017-05-02 Correlogic Systems Inc marcadores preditivos para o câncer ovariano
US20090046274A1 (en) * 2007-08-16 2009-02-19 Mchugh Mark A Light Scattering Methods and Systems Using Supercritical Fluid Solvents to Measure Polymer Molecular Weight and Molecular Weight Distribution
JP2010538005A (ja) * 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
EP2195340A4 (de) 2007-08-28 2011-05-11 Uab Research Foundation Synthetische apolipoprotein e-imitierende polypeptide und verwendungsverfahren
US20090134325A1 (en) * 2007-11-27 2009-05-28 Goldman Mildred M Methods for detecting estradiol by mass spectrometry
US8916385B2 (en) * 2007-12-13 2014-12-23 Quest Diagnostics Investments, Inc. Methods for detecting estrone by mass spectrometry
US9468758B2 (en) 2008-11-27 2016-10-18 E-Qure Corp. Wound diagnosis
US8855779B2 (en) * 2008-11-27 2014-10-07 Adb International Group Inc. Methods of diagnosis and treatment of wounds, methods of screening for electrical markers for wounds prognosis in patients
WO2010100816A1 (ja) * 2009-03-05 2010-09-10 株式会社 日立ハイテクノロジーズ 分析装置
KR101069629B1 (ko) * 2009-12-29 2011-10-05 한국기초과학지원연구원 파이프라인방식의 이온 싸이클로트론 공명 질량 분석 제어장치 및 방법
EP2550365B1 (de) 2010-03-22 2018-07-04 Stemina Biomarker Discovery, Inc. Vorhersage der entwicklung der toxizität von pharmazeutika für menschen mithilfe menschlicher stammzellen und metabolome
US9459247B2 (en) * 2010-03-29 2016-10-04 Academia Sinica Quantitative measurement of nano/micro particle endocytosis with cell mass spectrometry
US9673030B2 (en) 2010-05-17 2017-06-06 Emory University Computer readable storage mediums, methods and systems for normalizing chemical profiles in biological or medical samples detected by mass spectrometry
EP2447980B1 (de) * 2010-11-02 2019-05-22 Thermo Fisher Scientific (Bremen) GmbH Verfahren zur Herstellung eines Massenspektrums mit verbessertem Auflösungsvermögen
JP5408107B2 (ja) * 2010-11-10 2014-02-05 株式会社島津製作所 Ｍｓ／ｍｓ型質量分析装置及び同装置用プログラム
CA2823324C (en) 2010-12-28 2019-12-31 Quest Diagnostics Investments Incorporated Quantitation of insulin by mass spectrometry
US8728824B2 (en) 2011-06-22 2014-05-20 Quest Diagnostics Investments Inc. Mass spectrometric determination of fatty acids
JP2014526685A (ja) 2011-09-08 2014-10-06 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア 代謝流量測定、画像化、および顕微鏡法
EP3435088A1 (de) 2011-12-07 2019-01-30 GlaxoSmithKline LLC Verfahren zur bestimmung der skelettmuskelmasse des gesamten körpers
US8946648B2 (en) 2012-01-19 2015-02-03 Princeton Gamma-Tech Instruments Llc Dual range digital nuclear spectrometer
DE102012100781B4 (de) * 2012-01-31 2013-08-14 Eberhard-Karls-Universität Tübingen Universitätsklinikum Forensisches Verfahren
US9134319B2 (en) 2013-03-15 2015-09-15 The Regents Of The University Of California Method for replacing biomarkers of protein kinetics from tissue samples by biomarkers of protein kinetics from body fluids after isotopic labeling in vivo
US10335789B2 (en) * 2013-07-26 2019-07-02 The Trustees Of The University Of Pennsylvania Magnetic separation filters for microfluidic devices
KR20170028322A (ko) * 2014-05-28 2017-03-13 비토 엔브이 상이한 생물학적 샘플의 혼합물에 포함된 화학적 화합물의 상대적인 정량화 방법
CN107074923B (zh) 2014-07-31 2021-08-03 Uab研究基金会 Apoe模拟肽及对清除血浆胆固醇的较高效力
US10324082B2 (en) 2015-03-03 2019-06-18 Quest Diagnostics Investments Llc Methods for quantitation of insulin levels by mass spectrometry
CN106053299B (zh) * 2015-04-12 2020-10-30 艾斯拜克特Ai有限公司 非圆形横截面管道中的流体的nmr成像
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists
CN110914691B (zh) 2017-03-31 2024-07-26 奎斯特诊断投资有限公司 用于定量胰岛素和c-肽的方法
SG11202110398QA (en) 2019-03-28 2021-10-28 Univ California Concurrent analysis of multiple analytes
CN114651058B (zh) 2019-08-05 2023-07-28 禧尔公司 用于样品制备、数据生成和蛋白质冠分析的系统和方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4224031A (en) 1977-11-15 1980-09-23 Mee John M L CI Mass spectrometric analysis of physiologically active compounds
GB9315847D0 (en) * 1993-07-30 1993-09-15 Isis Innovation Tag reagent and assay method
US5538897A (en) 1994-03-14 1996-07-23 University Of Washington Use of mass spectrometry fragmentation patterns of peptides to identify amino acid sequences in databases
US6177266B1 (en) * 1996-04-29 2001-01-23 The United States Of America As Represented By The Secretary Of The Army Rapid identification of bacteria by mass spectrometry
US6207370B1 (en) * 1997-09-02 2001-03-27 Sequenom, Inc. Diagnostics based on mass spectrometric detection of translated target polypeptides
US6428956B1 (en) * 1998-03-02 2002-08-06 Isis Pharmaceuticals, Inc. Mass spectrometric methods for biomolecular screening
WO1999046047A2 (en) 1998-03-10 1999-09-16 Large Scale Proteomics Corporation Detection and characterization of microorganisms
US6723564B2 (en) 1998-05-07 2004-04-20 Sequenom, Inc. IR MALDI mass spectrometry of nucleic acids using liquid matrices
US6037118A (en) 1998-05-14 2000-03-14 University Of Maryland Baltimore County Viral characterization by direct detection of capsid proteins
WO2000003240A1 (en) 1998-07-10 2000-01-20 Cetek Corporation Method to detect and analyze tight-binding ligands in complex biological samples
US6183950B1 (en) * 1998-07-31 2001-02-06 Colorado School Of Mines Method and apparatus for detecting viruses using primary and secondary biomarkers
WO2000029987A1 (en) 1998-11-17 2000-05-25 University Of Maryland Methods for identifying and classifying organisms by mass spectrometry and database searching
WO2000048004A1 (en) * 1999-02-11 2000-08-17 Maxygen, Inc. High throughput mass spectrometry
CA2298181C (en) 2000-02-02 2006-09-19 Dayan Burke Goodnough Non-targeted complex sample analysis
US6680203B2 (en) * 2000-07-10 2004-01-20 Esperion Therapeutics, Inc. Fourier transform mass spectrometry of complex biological samples

Also Published As

Publication number Publication date
WO2002004957A2 (en) 2002-01-17
US6680203B2 (en) 2004-01-20
ES2259668T3 (es) 2006-10-16
WO2002004957A3 (en) 2002-11-21
JP2004503749A (ja) 2004-02-05
HK1051068A1 (en) 2003-07-18
US20050118650A1 (en) 2005-06-02
EP1299730A2 (de) 2003-04-09
AU2001280517A1 (en) 2002-01-21
DE60116882T2 (de) 2006-11-02
CA2415940A1 (en) 2002-01-17
US6974702B2 (en) 2005-12-13
EP1299730B1 (de) 2006-01-25
DE60116882D1 (de) 2006-04-13
US20020019023A1 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
ATE316656T1 (de) Fourier-transformation-massenspektrometrie von komplizierten biologischen proben
Sinha et al. A beginner’s guide to mass spectrometry–based proteomics
Freeman et al. Proteomics for protein expression profiling in neuroscience
Garcia et al. Chemical derivatization of histones for facilitated analysis by mass spectrometry
Lemmel et al. Differential quantitative analysis of MHC ligands by mass spectrometry using stable isotope labeling
Tang et al. A new cross-linking strategy: protein interaction reporter (PIR) technology for protein–protein interaction studies
Sinz Chemical cross‐linking and mass spectrometry for mapping three‐dimensional structures of proteins and protein complexes
Zhang et al. Fractionation of isotopically labeled peptides in quantitative proteomics
Chen et al. Optimization of mass spectrometry-compatible surfactants for shotgun proteomics
Gao et al. Screening derivatized peptide libraries for tight binding inhibitors to carbonic anhydrase II by electrospray ionization-mass spectrometry
Muller et al. Cleavable cross-linker for protein structure analysis: reliable identification of cross-linking products by tandem MS
Hsu et al. Beyond quantitative proteomics: signal enhancement of the a1 ion as a mass tag for peptide sequencing using dimethyl labeling
Borchers et al. Identification of in-gel digested proteins by complementary peptide mass fingerprinting and tandem mass spectrometry data obtained on an electrospray ionization quadrupole time-of-flight mass spectrometer
WO2002082051A3 (en) An integrated high throughput system for the analysis of biomolecules
Clarke et al. Mapping a noncovalent protein–peptide interface by top-down FTICR mass spectrometry using electron capture dissociation
Schriemer et al. Combining avidin− biotin chemistry with matrix-assisted laser desorption/ionization mass spectrometry
Bakhtiar et al. Biological mass spectrometry: a primer
Soldi et al. Mass spectrometry-based proteomics for the analysis of chromatin structure and dynamics
Zhang et al. Identification of mammalian cell lines using MALDI-TOF and LC-ESI-MS/MS mass spectrometry
Mädler et al. MALDI-ToF mass spectrometry for studying noncovalent complexes of biomolecules
Yang et al. Recent technical progress in sample preparation and liquid-phase separation-mass spectrometry for proteomic analysis of mass-limited samples
JPH1025299A (ja) 整列ペプチド、及びそれを用いたタンパク質の結合・相互作用部位検出方法
Zappacosta et al. N-terminal isotope tagging strategy for quantitative proteomics: results-driven analysis of protein abundance changes
Bielik et al. Historical overview of glycoanalysis
Pashkova et al. Coumarin tags for analysis of peptides by MALDI-TOF MS and MS/MS. 2. Alexa Fluor 350 tag for increased peptide and protein identification by LC-MALDI-TOF/TOF MS

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties